Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 13;7:e2200421. doi: 10.1200/PO.22.00421

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — Co-occurring genomic alterations in subprotocols S1 and S2. Co-occurring genomic alterations using the NCI-MATCH assay color-coded by: left: variant type; top: copy-number variant (pink), SNV (red), indel (purple), and unified gene fusion (magenta) for each eligible patient; and bottom: information regarding histology and best response on treatment: PR, SD, PD, and UE. Cholangio, cholangiocarcinoma; endo, endocrine cancer; gall, gallbladder cancer; GBM, glioblastoma; neuro, peripheral nerve sheath tumor or neurofibroma; neuroendo, neuroendocrine carcinoma; ovar/fallop, ovarian/fallopian tube cancer; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; SNV, single-nucleotide variant; stom/small int, gastric or small intestine carcinoma; UE, unevaluable.